Various studies have addressed the relationship between overall tumor mutation load/neoantigen burden and ICB response in NSCLC and melanoma, in the context of anti-PD-1 and anti-CTLA-4 monotherapy [69,70,71,72]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.